| HALAMKA, Magdalena, Jakub CVEK, Jiří KUBEŠ, Eva ZÁVADOVÁ, Pavel KOMÍNEK, Jaroslav HORÁČEK, Ladislav DUŠEK a David FELTL. Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer. Oral oncology. 2011, roč. 47, č. 8, s. 763-767. ISSN 1368-8375. Dostupné z: https://dx.doi.org/10.1016/j.oraloncology.2011.05.009. |
Další formáty:
BibTeX
LaTeX
RIS
@article{950803,
author = {Halamka, Magdalena and Cvek, Jakub and Kubeš, Jiří and Závadová, Eva and Komínek, Pavel and Horáček, Jaroslav and Dušek, Ladislav and Feltl, David},
article_number = {8},
doi = {http://dx.doi.org/10.1016/j.oraloncology.2011.05.009},
keywords = {Head and neck cancer; Celecoxib; Radiotherapy; VEGF; COX-2 expression},
language = {eng},
issn = {1368-8375},
journal = {Oral oncology},
title = {Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer},
volume = {47},
year = {2011}
}
TY - JOUR
ID - 950803
AU - Halamka, Magdalena - Cvek, Jakub - Kubeš, Jiří - Závadová, Eva - Komínek, Pavel - Horáček, Jaroslav - Dušek, Ladislav - Feltl, David
PY - 2011
TI - Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer
JF - Oral oncology
VL - 47
IS - 8
SP - 763-767
EP - 763-767
SN - 13688375
KW - Head and neck cancer
KW - Celecoxib
KW - Radiotherapy
KW - VEGF
KW - COX-2 expression
N2 - Celebrex and radiotherapy in advanced head and neck cancer. This phase I dose-escalation study seeks to determine the phase II recommended dose of cyclooxygenase type 2 (COX-2) inhibitor in patients with locally advanced squamous cell head and neck (H&N) cancer, treated with accelerated radiotherapy. Anti-vasculogenic effect of this treatment on serum vascular endothelial growth factor (VEGF) is examined. Patients were irradiated with curative intent (72 Gy in 6 weeks). Celecoxib was administered throughout the radiotherapy course. Serum VEGF level were tested during radiotherapy and in follow-up. Tumor specimens were stained to quantify the COX-2 expression. Thirty-two patients completed the treatment. The dose of celecoxib was escalated (200, 400 and 800 mg bid, then de-escalated to 600 mg bid). The acute toxicity related to the treatment in the first and second cohort did not reach grade III; in the third cohort three patients had grade III radiation toxicity and one had celecoxib-related toxicity. In the last fourth cohort the toxicity was acceptable. Significant VEGF level drop (p = 0.011) was found between radiation day 1 and post-treatment visit. Significant decrease (p = 0.022) of the VEGF level was shown in patients with high COX-2 expression in the tumor. Phase II recommended dose of celecoxib combined with accelerated radiotherapy in advanced H&N cancer was 600 mg bid. A significant decrease of the post-treatment serum VEGF level compared to the initial level was noticed only in patients with high COX-2 expression in tumors.
ER -
HALAMKA, Magdalena, Jakub CVEK, Jiří KUBEŠ, Eva ZÁVADOVÁ, Pavel KOMÍNEK, Jaroslav HORÁČEK, Ladislav DUŠEK a David FELTL. Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer. \textit{Oral oncology}. 2011, roč.~47, č.~8, s.~763-767. ISSN~1368-8375. Dostupné z: https://dx.doi.org/10.1016/j.oraloncology.2011.05.009.
|
